Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Pacira BioSciences Inc’s stock clocked out at $19.83, down -0.20% from its previous closing price of $19.87. In other words, the price has decreased by -$0.20 from its previous closing price. On the day, 0.69 million shares were traded. PCRX stock price reached its highest trading level at $20.0057 during the session, while it also had its lowest trading level at $19.34.
Ratios:
To gain a deeper understanding of PCRX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.02 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.73. For the most recent quarter (mrq), Quick Ratio is recorded 1.89 and its Current Ratio is at 2.25. In the meantime, Its Debt-to-Equity ratio is 0.86 whereas as Long-Term Debt/Eq ratio is at 0.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on August 13, 2024, Downgraded its rating to Sell and sets its target price to $8 from $30 previously.
On August 12, 2024, RBC Capital Mkts Downgraded its rating to Sector Perform which previously was Outperform and also lowered its target price recommendation from $37 to $14.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 13 ’24 when GAUGLER DARYL sold 500 shares for $19.76 per share. The transaction valued at 9,880 led to the insider holds 115,200 shares of the business.
GAUGLER DARYL bought 500 shares of PCRX for $9,880 on Dec 13 ’24. On Sep 13 ’24, another insider, GAUGLER DARYL, who serves as the Chief Operating Officer of the company, sold 500 shares for $12.86 each. As a result, the insider received 6,430 and left with 115,700 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCRX now has a Market Capitalization of 915614528 and an Enterprise Value of 1108075264. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.32 while its Price-to-Book (P/B) ratio in mrq is 1.22. Its current Enterprise Value per Revenue stands at 1.594 whereas that against EBITDA is 6.224.
Stock Price History:
Over the past 52 weeks, PCRX has reached a high of $35.95, while it has fallen to a 52-week low of $11.16. The 50-Day Moving Average of the stock is 13.86%, while the 200-Day Moving Average is calculated to be -9.29%.
Shares Statistics:
It appears that PCRX traded 758.28K shares on average per day over the past three months and 1047470 shares per day over the past ten days. A total of 46.15M shares are outstanding, with a floating share count of 44.58M. Insiders hold about 3.45% of the company’s shares, while institutions hold 112.54% stake in the company. Shares short for PCRX as of 1732838400 were 4795767 with a Short Ratio of 6.32, compared to 1730332800 on 5462899. Therefore, it implies a Short% of Shares Outstanding of 4795767 and a Short% of Float of 15.120000000000001.
